FAQs
1. How is Alzheimer’s different from normal aging?
Normal aging may cause minor changes like forgetting names or misplacing objects, but people remain independent. In contrast, Alzheimer’s involves more severe memory loss that interferes with daily life and progressively worsens. This is accompanied by broader issues like language problems, confusion, poor judgment, and difficulty with complex tasks.
2. What role does diet play in Alzheimer’s risk?
While diet alone cannot prevent Alzheimer’s, it is one of the most modifiable risk factors. Diets like the Mediterranean or MIND diet emphasize leafy greens, berries, whole grains, fish, olive oil, and nuts, which may lower risk by reducing inflammation and supporting vascular health. In contrast, diets high in processed foods, sugar, and saturated fats are associated with increased risk.
3. Are there gender differences in Alzheimer’s disease?
Yes. Women are disproportionately affected, with about two-thirds of Alzheimer’s patients being female. This is partly because women generally live longer, but biological factors likely also play a role. Hormonal changes after menopause, genetic differences, and brain structural variations may contribute to women’s higher vulnerability.
4. Is there a link between Alzheimer’s and other diseases?
Yes, many vascular and metabolic conditions increase Alzheimer’s risk. Diabetes, hypertension, obesity, and stroke damage blood vessels and weaken brain health. Depression and chronic stress are linked to faster cognitive decline. This overlap suggests that preventive care for cardiovascular and mental health may lower dementia risk.
Reference
1. Scheltens, P., De Strooper, B., Kivipelto, M., et al. (2021). Alzheimer’s disease. The Lancet, 397(10284), 1577-1590.
2. Hippius, H., & Neundörfer, G. (2003). The discovery of Alzheimer’s disease. Dialogues in clinical neuroscience, 5(1), 101-108.
3. Reitz, C. (2012). Alzheimer′ s disease and the amyloid cascade hypothesis: a critical review. International journal of Alzheimer’s disease, 2012(1), 369808.
4. Sepulveda-Diaz, J. E., Naini, S. M. A., Huynh, M. B., et al. (2015). HS3ST2 expression is critical for the abnormal phosphorylation of tau in Alzheimer’s disease-related tau pathology. Brain, 138(5), 1339.
5. Fakhoury, M. (2018). Microglia and astrocytes in Alzheimer’s disease: implications for therapy. Current neuropharmacology, 16(5), 508-518.
6. Bayer, T. A., & Wirths, O. (2010). Intracellular accumulation of amyloid-Beta-a predictor for synaptic dysfunction and neuron loss in Alzheimer’s disease. Frontiers in aging neuroscience, 2, 1359.
7. Sun, Q., Zhang, J., Li, A., et al. (2022). Acetylcholine deficiency disrupts extratelencephalic projection neurons in the prefrontal cortex in a mouse model of Alzheimer’s disease. Nature communications, 13(1), 998.
8. Guerreiro, R., & Bras, J. (2015). The age factor in Alzheimer’s disease. Genome medicine, 7(1), 106.
9. Donix, M., Small, G. W., & Bookheimer, S. Y. (2012). Family history and APOE-4 genetic risk in Alzheimer’s disease. Neuropsychology review, 22(3), 298-309.
10. Cruchaga, C., Chakraverty, S., Mayo, K., et al. (2012). Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer’s disease families. PloS one, 7(2), e31039.
11. Griciuc, A., Patel, S., Federico, A. N., et al. (2019). TREM2 acts downstream of CD33 in modulating microglial pathology in Alzheimer’s disease. Neuron, 103(5), 820-835.
12. Andrew, M. K., & Tierney, M. C. (2018). The puzzle of sex, gender and Alzheimer’s disease: Why are women more often affected than men?. Women’s Health, 14, 1745506518817995.
13. de Bruijn, R. F., & Ikram, M. A. (2014). Cardiovascular risk factors and future risk of Alzheimer’s disease. BMC medicine, 12(1), 130.
14. Lu, Z., Harris, T. B., Shiroma, E. J., et al. (2018). Patterns of physical activity and sedentary behavior for older adults with Alzheimer’s disease, mild cognitive impairment, and cognitively normal in Hong Kong. Journal of Alzheimer’s Disease, 66(4), 1453-1462.
15. Vasefi, M., Hudson, M., & Ghaboolian-Zare, E. (2019). Diet associated with inflammation and Alzheimer’s disease. Journal of Alzheimer’s disease reports, 3(1), 299-309.
16. Heymann, D., Stern, Y., Cosentino, S., et al. (2016). The association between alcohol use and the progression of Alzheimer’s disease. Current Alzheimer Research, 13(12), 1356-1362.
17. Li, Y., Li, Y., Li, X., et al. (2017). Head injury as a risk factor for dementia and Alzheimer’s disease: a systematic review and meta-analysis of 32 observational studies. PloS one, 12(1), e0169650.
18. Andrade, A. G., Bubu, O. M., Varga, A. W., et al. (2018). The relationship between obstructive sleep apnea and Alzheimer’s disease. Journal of Alzheimer’s Disease, 64(s1), S255-S270.
19. Stern, Y. (2012). Cognitive reserve in ageing and Alzheimer’s disease. The Lancet Neurology, 11(11), 1006-1012.
20. Drinkwater, E., Davies, C., & Spires‐Jones, T. L. (2022). Potential neurobiological links between social isolation and Alzheimer’s disease risk. European Journal of Neuroscience, 56(9), 5397-5412.
21. Moulton, P. V., & Yang, W. (2012). Air pollution, oxidative stress, and Alzheimer′ s disease. Journal of environmental and public health, 2012(1), 472751.
22. Caselli, R. J., & Reiman, E. M. (2012). Characterizing the preclinical stages of Alzheimer’s disease and the prospect of presymptomatic intervention. Journal of Alzheimer’s Disease, 33(s1), S405-S416.
23. Knopman, D. S., & Petersen, R. C. (2014, October). Mild Cognitive Impairment and Mild Dementia: A Clinical Perspective. In Mayo Clinic proceedings (Vol. 89, No. 10, p. 1452).
24. Cerejeira, J., Lagarto, L., & Mukaetova-Ladinska, E. B. (2012). Behavioral and psychological symptoms of dementia. Frontiers in neurology, 3, 73.
25. Brucki, S. M. D., Aprahamian, I., Borelli, W. V., et al. (2022). Management in severe dementia: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. Dementia & Neuropsychologia, 16(3 Suppl 1), 101.
26. Shen, H. N., Lu, C. L., & Li, C. Y. (2012). Dementia increases the risks of acute organ dysfunction, severe sepsis and mortality in hospitalized older patients: a national population-based study, 7(8), e42751.
27. Jia, X., Wang, Z., Huang, F., et al. (2021). A comparison of the Mini-Mental State Examination (MMSE) with the Montreal Cognitive Assessment (MoCA) for mild cognitive impairment screening in Chinese middle-aged and older population: a cross-sectional study. BMC psychiatry, 21(1), 485.
28. Hansson, O., Blennow, K., Zetterberg, H., et al. (2023). Blood biomarkers for Alzheimer’s disease in clinical practice and trials. Nature aging, 3(5), 506-519.
29. Cuttler, J. M., Moore, E. R., Hosfeld, V. D., et al. (2016). Treatment of Alzheimer disease with CT scans: a case report. Dose-response, 14(2), 1559325816640073.
30. Li, D. D., Zhang, Y. H., Zhang, W., et al. (2019). Meta-analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease. Frontiers in neuroscience, 13, 472.
31. Ameen, T. B., Kashif, S. N., Abbas, S. M. I., et al. (2024). Unraveling Alzheimer’s: the promise of aducanumab, lecanemab, and donanemab. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 60(1), 72.
32. Mintzer, J., Donovan, K. A., Kindy, A. Z., et al. (2019). Lifestyle choices and brain health. Frontiers in medicine, 6, 204.
33. Gauthier, S., Cummings, J., Ballard, C., et al. (2010). Management of behavioral problems in Alzheimer’s disease. International psychogeriatrics, 22(3), 346-372.
34. Elif, K., Taşkapilioğlu, Ö., & Bakar, M. (2017). Caregiver burden in different stages of Alzheimer’s disease. Archives of Neuropsychiatry, 54(1), 82.
35. Cummings, J. L., Tong, G., & Ballard, C. (2019). Treatment combinations for Alzheimer’s disease: current and future pharmacotherapy options. Journal of Alzheimer’s Disease, 67(3), 779-794.
36. Rasmussen, J., & Langerman, H. (2019). Alzheimer’s Disease–Why We Need Early Diagnosis. Degenerative Neurological and Neuromuscular Disease, 9, 123.
37. Tsou, Y. H., Zhang, X. Q., Zhu, H., et al. (2017). Drug Delivery to the Brain across the Blood–Brain Barrier Using Nanomaterials. Small, 1701921.
38. Reitz, C. (2016). Toward precision medicine in Alzheimer’s disease. Annals of translational medicine, 4(6), 107.
39. Oxford, A. E., Stewart, E. S., & Rohn, T. T. (2020). Clinical trials in Alzheimer’s disease: a hurdle in the path of remedy. International Journal of Alzheimer’s Disease, 2020(1), 5380346.
40. Doran, S. J., & Sawyer, R. P. (2024). Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications. Frontiers in Neuroscience, 18, 1326784.
41. Chen, Y., & Yu, Y. (2023). Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation. Journal of neuroinflammation, 20(1), 165.
42. Attems, J., & Jellinger, K. A. (2014). The overlap between vascular disease and Alzheimer’s disease-lessons from pathology. BMC medicine, 12(1), 206.
43. Narengaowa, Kong, W., Lan, F., Awan, U. F., et al. (2021). The oral-gut-brain AXIS: the influence of microbes in Alzheimer’s disease. Frontiers in cellular neuroscience, 15, 633735.
44. Song, S., Li, T., Lin, W., et al. (2025). Application of artificial intelligence in Alzheimer’s disease: A bibliometric analysis. Frontiers in Neuroscience, 19, 1511350.
45. Lu, L., Yu, X., Cai, Y., et al. (2021). Application of CRISPR/Cas9 in Alzheimer’s disease. Frontiers in neuroscience, 15, 803894.
46. Liu, X. Y., Yang, L. P., & Zhao, L. (2020). Stem cell therapy for Alzheimer’s disease. World journal of stem cells, 12(8), 787.
47. Deb, A., Thornton, J. D., Sambamoorthi, U., et al. (2017). Direct and indirect cost of managing Alzheimer’s disease and related dementias in the United States. Expert review of pharmacoeconomics & outcomes research, 17(2), 189-202.
48. Elif, K., Taşkapilioğlu, Ö., & Bakar, M. (2017). Caregiver burden in different stages of Alzheimer’s disease. Archives of Neuropsychiatry, 54(1), 82.
49. Karlawish, J. (2011). Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease. Neurology, 77(15), 1487-1493.
50. Rio, R. (2018). A community-based music therapy support group for people with Alzheimer’s disease and their caregivers: A sustainable partnership model. Frontiers in medicine, 5, 293.